Facetten
Zugriff
Einrichtung
Medientyp
- Text 4
Karte
Erscheinungsjahr
Autor/in
- Lauseker, Michael 4
- Müller, Martin C 4
- Proetel, Ulrike
- Hanfstein, Benjamin 3
- Pletsch, Nadine 3
- alle zeigen
Sprache
- Englisch 4
4 Einträge gefunden
-
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
- Hehlmann, Rüdiger
- Müller, Martin C
- Lauseker, Michael
- Hanfstein, Benjamin
- Fabarius, Alice
- Schreiber, Annette
- Proetel, Ulrike
-
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
- Kalmanti, Lida
- Saussele, Susanne
- Lauseker, Michael
- Proetel, Ulrike
- Müller, Martin C
- Hanfstein, Benjamin
- Schreiber, Annette
-
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
- Proetel, Ulrike
- Pletsch, Nadine
- Lauseker, Michael
- Müller, Martin C
- Hanfstein, Benjamin
- Krause, Stefan W
- Kalmanti, Lida
-
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
- Hehlmann, Rüdiger
- Lauseker, Michael
- Jung-Munkwitz, Susanne
- Leitner, Armin
- Müller, Martin C
- Pletsch, Nadine
- Proetel, Ulrike